Market Place
Sourcing Support
FDA Confirms Para IV Patent Litigation for Cresemba Capsules
31 Oct 2024 //
FDA
Strong Cresemba Sales In Asia Pacific Triggers 4th Milestone Payment
10 Oct 2024 //
GLOBENEWSWIRE
FDA Confirms Para IV Patent Litigation for Cresemba Injection
09 Oct 2024 //
FDA
Cresemba Sales Trigger in Europe USD 25 Million Milestone Payment
06 Sep 2024 //
GLOBENEWSWIRE
EU Approves Pediatric Use of Cresemba®; CHF 10M Milestone Payment to Basilea
27 Aug 2024 //
GLOBENEWSWIRE
EC Approves Pediatric Use Of Cresemba, Triggering CHF 10M Payment To Basilea
27 Aug 2024 //
GLOBENEWSWIRE
Basilea Receives Milestone Payment For Strong Cresemba Sales In Asia Pacific
21 Aug 2024 //
GLOBENEWSWIRE
FDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA
11 Mar 2024 //
PR NEWSWIRE
Continued strong Cresemba sales performance in Asia Pacific
11 Mar 2024 //
GLOBENEWSWIRE
Basilea announces that FDA approves expanded use of antifungal Cresemba
11 Dec 2023 //
GLOBENEWSWIRE
FDA Approves Expanded Use of CRESEMBA in Children with Invasive Aspergillosis
08 Dec 2023 //
PR NEWSWIRE
Continued strong Cresemba (isavuconazole) sales performance in Asia Pacific
20 Nov 2023 //
GLOBENEWSWIRE
FDA Accepts Astellas` sNDA for CRESEMBA® (isavuconazonium sulfate) in Children
10 Aug 2023 //
PR NEWSWIRE
Continued strong Cresemba sales by Pfizer trigger USD 26 million sales
08 Jun 2023 //
GLOBENEWSWIRE
Continued Cresemba sales triggers second sales milestone payment to Basilea
07 Feb 2023 //
GLOBENEWSWIRE
Continued strong Cresemba sales by Astellas in the U.S. trigger CHF 20 million
09 Jan 2023 //
GLOBENEWSWIRE
Basilea announces regulatory approval of antifungal Cresemba
23 Dec 2022 //
GLOBENEWSWIRE
Basilea announces approval for additional formulation of antifungal Cresemba
24 Jun 2022 //
GLOBENEWSWIRE
Cresemba sales in Asia Pacific region trigger sales milestone payment to Basilea from Pfizer
17 Jun 2022 //
PRESS RELEASE
Cresemba sales in Asia Pacific region trigger sales milestone payment
17 Jun 2022 //
GLOBENEWSWIRE
Basilea announces approval of antifungal Cresemba for invasive aspergillosis
13 Jan 2022 //
GLOBENEWSWIRE
Asahi Kasei filed NDA for marketing authorization of isavuconazole in Japan
30 Sep 2021 //
BIOSPACE
Basilea reports acceptance for regulatory review of Pfizer’s MKT authorization
07 Aug 2020 //
GLOBENEWSWIRE
Basilea reports the launch of antifungal Cresemba® (isavuconazole) in Taiwan
15 Jul 2020 //
GLOBENEWSLWIRE
Basilea reports marketing authorization of antifungal Cresemba® in Brazil
29 Oct 2019 //
GLOBENEWSWIRE
First phase 3 data back Scynexis` new-class antifungal
31 Jan 2019 //
FIERCE BIOTECH
Pfizer Enters into Agreement to Develop & Commercialize CRESEMBA
01 Dec 2017 //
PRESS RELEASE
Pfizer Completes License Agreement for Rights In EU For CRESEMBA isavuconazole
20 Jul 2017 //
PFIZER
Basilea announces completion of the license agreement with Pfizer for Cresemba
19 Jul 2017 //
GLOBENEWSWIRE
SMC accepts three new drugs for NHS use, but bans two
12 Apr 2016 //
PHARMATIMES
Edison Issues Initiation on Basilea Pharmaceutica
24 Mar 2016 //
PR NEWSWIRE
Basilea dumps its $190M IPO plan as the U.S. market sputters
09 Dec 2015 //
FIERCE BIOTECH
